The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:308-309 January 20, 2005 Number 3
NextNext

Treatment of Pulmonary Arterial Hypertension

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Humbert, M.
-PubMed Citation
To the Editor: In their review of treatment for pulmonary arterial hypertension, Humbert et al. (Sept. 30 issue)1 discuss therapeutic strategies with the use of prostacyclin and endothelin-receptor antagonists. Potential future therapies focus on other vasodilators and combination therapy. However, in addition, on the basis of pathophysiological mechanisms, there might be a role for immunosuppressive therapy. Several case reports show that in patients with systemic lupus erythematosus, the use of immunosuppressive drugs in the absence of disease activity results in an improvement of severe pulmonary arterial hypertension.2,3 Recently, the role of inflammation in pulmonary arterial hypertension has been described.4 Moreover, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.